The metabolite beta-aminoisobutyric acid and physical inactivity among hemodialysis patients by Molfino, Alessio et al.
lable at ScienceDirect
Nutrition 34 (2017) 101–107Contents lists avaiNutrition
journal homepage: www.nutr i t ionjrnl .comApplied nutritional investigationThe metabolite beta-aminoisobutyric acid and physical inactivity
among hemodialysis patients
Alessio Molfino M.D., Ph.D. a,*, Maria Ida Amabile M.D., Ph.D. a,
Thomas Ammann M.D. b, Alessio Farcomeni Ph.D. c, Luana Lionetto Ph.D. d,
Maurizio Simmaco M.D. e, Silvia Lai M.D. a, Alessandro Laviano M.D. a,
Filippo Rossi Fanelli M.D. a, Maria Grazia Chiappini M.D. b,
Maurizio Muscaritoli M.D. a
aDepartment of Clinical Medicine, Sapienza University of Rome, Rome, Italy
bHemodialysis Unit, Fatebenefratelli ‘Isola Tiberina’ Hospital, Rome, Italy
cDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy
d Personalized Medicine Unit, Istituto Dermopatico dell’Immacolata-IRCCS, Rome, Italy
eNeuroscience, Mental Health and Sense Organs Department, Advanced Molecular Diagnostics Unit, Sant’Andrea Hospital, Rome, Italya r t i c l e i n f o
Article history:
Received 21 February 2016
Accepted 19 July 2016
Keywords:
Beta-aminoisobutyric acid (BAIBA)
Physical activity
Hemodialysis
Body compositionThis study was supported by Institutional funds
Medicine, Sapienza – University of Rome). AM des
research, analyzed the data, and wrote the paper.
collected the data, and wrote the paper. TA collected
and performed statistical analyses. LL performed labor
laboratory data. SL conducted research. AL designed r
paper. FRF designed research. MGC conducted resea
http://dx.doi.org/10.1016/j.nut.2016.07.012
0899-9007/ 2016 Elsevier Inc. All rights reserved.a b s t r a c t
Objective: Physical inactivity is frequent in patients on hemodialysis (HD), and represents a reliable
predictor of morbidity and mortality. Beta-aminoisobutyric acid (BAIBA) is a contraction-induced
myokine, the plasma levels of which increase with exercise and are inversely associated with
metabolic risk factors. The aim of this study was to ascertain whether physical inactivity and
clinical parameters relate to plasma BAIBA levels in this patient population.
Methods: Adult patients on HD were included, and the presence of physical inactivity was assessed.
BAIBA levels were measured in these patients and in healthy individuals. We assessed barriers to
physical activity, including 23 items regarding psychophysical and financial barriers. Body
composition was assessed by bioimpedance and muscle strength by handgrip dynamometer.
Nonparametric tests and logistic regression analyses were performed.
Results: Forty-nine patients on HD were studied; 49% were physically active and 51% were inactive.
Of the patients, 43 reported barriers to physical activity and 61% of inactive patients reported three
or more barriers. BAIBA levels were lower in patients on HD with respect to controls (P < 0.001).
Stratifying HD patients as active and inactive, both groups showed significantly lower BAIBA levels
versus controls (P ¼ 0.0005, P < 0.001, respectively). Nondiabetic patients on HD showed increased
BAIBA levels compared with diabetic patients (P < 0.001). Patients on HD endorsing the two most
frequent barriers showed lower BAIBA levels than those not reporting these barriers (P ¼ 0.006).
Active patients showed higher intracellular water (%) (P ¼ 0.008), and active and inactive patients
showed significant correlation between total body muscle mass and handgrip strength (P ¼ 0.04,
P ¼ 0.005, respectively).
Conclusions: Physical inactivity is highly prevalent among patients on HD and BAIBA correlates
with barriers to physical activity reported by inactive patients.
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Physical activity is significantly reduced in patients on he-
modialysis (HD) [1]. Independently from age, a low level of
physical activity may significantly contribute to frailty and
disability by reducing physical performance and may determine
protein-energy wasting, which is highly prevalent among this
patient population [2], by inducing skeletal muscle atrophy [1].
Low levels of physical activity have been associated with reduced
survival in dialysis patients and physical inactivity is a strong
predictor of cardiovascular mortality in HD [3]. The presence of
several comorbidities, in association with socioeconomic, psy-
chological, and cultural inabilities, plays a key role in condi-
tioning physical inactivity [4].
Although physical activity can be easily investigated using
quantitative tools, most physicians do not assess physical activity
or inactivity in patients on HD [5], and the choice of instrument
to be used depends on the patient’s activity level and on the
outcomes of interest. In particular, most of the questionnaires
used were not specifically designed to be implemented in dial-
ysis patients.
To our knowledge, there is no specific biomarker by which to
diagnose the reduced level of physical activity in dialysis pa-
tients, which could be useful for diagnosis and during follow-up
visits and would not be time consuming.
Recently, beta-aminoisobutyric acid (BAIBA) has been identi-
fied as a contraction-induced myokine [6]. BAIBA is a nonprotein
beta-amino acid generated by the catabolism of the branched-
chain amino acid valine. Skeletal muscle is a major site of
branched-chain amino acid utilization, the catabolism of which is
significantly increased during exercise [7,8]. The forced expression
of the muscle peroxisome proliferator-activated receptor-g
coactivator-1 a regulates BAIBA expression during exercise [6].
Available data suggest a possible link between valine use in skel-
etal muscle during exercise and beneficial effects of BAIBA in
inducing browning of white fat and hepatic b-oxidation through a
peroxisome proliferator-activated receptor-a-mediated mecha-
nism [5]. Thus, we hypothesized that BAIBA levels may be signif-
icantly reduced in patients with reduced physical activity. The
primary aim of this study was to assess the prevalence of physical
inactivity and its relationshipwith BAIBA levels as a possible novel
biomarker of physical activity in a cohort of patients on HD.
The secondary aim was to relate BAIBA levels with metabolic
and inflammatory alterations, body composition modifications,
and low muscle strength.
Material and methods
This cross-sectional study was performed on patients from the Dialysis Unit
of “Fatebenefratelli” Hospital, Isola Tiberina, in Rome, Italy. Adult men and
women on HDwhowere participants of a study investigating the role of nutrition
and quality of life were enrolled. The study was approved by the local ethics
committee (ethics committee registration n. 29/2013). Written informed consent
was obtained from all patients before enrollment in the study. More than 50
patients with end-stage renal disease were being treated in this hemodialysis
unit. All adult patients receiving HD in October 2014were recruited for this study.
Exclusion criteria included presence of highly catabolic diseases, such as cancer,
chronic infections, and AIDS, and the absence of informed consent. Patients were
maintained on a regular HD prescription, three times a week, for 4-h sessions.
Patient demographic and clinical characteristics
Participants were interviewed before or during dialysis session, and de-
mographic characteristics, including age, sex, weight, height, body mass index
(BMI), dialysis vintage, and Kt/V were registered. Hemoglobin and serum nutri-
tional and inflammatory biomarkersdincluding total proteins, cholesterol, tri-
glycerides, albumin, normalized protein catabolic rate, C-reactive protein,
lymphocytes, transferrin, blood urea nitrogen, sodium, potassium, phosphorus,and creatininedwere also recorded. Additionally, comorbidities, blood pressure
control, and current therapies were collected. C-reactive protein was measured
by nephelometric assay (detection limit ¼ 0.5 mg/dL).
Body impedance analysis
Body impedance analysis was used to assess body composition, in particular
to evaluatemusclemass and adiposity [9], andwas performed 1 h after the end of
the second HD session of the week, with the patient maintaining a supine po-
sition for this period, using a single-frequency (50 Hz) instrument (Model 101,
Akern, Florence, Italy). Data previously obtained by body impedance analysis as
soon as 15 min after starting the dialysis session has been predictable [9]. The
electrodes and recording pads were placed on the nonaccess side of the body.
Two pairs of electrodes were placed on the hand to the foot for injecting current
and on the wrist to the ankle for measuring voltage. Total body water was esti-
mated using the resistance extrapolated to frequency [9]. We estimated the hy-
dration of fat free mass (FFM) at 73% (FFM ¼ [total body water]/0.73) and
extracellular water was estimated from resistance extrapolated to zero frequency
[9–11]. Additional parameters, including body cell mass, were calculated using a
program provided by the producer. We calculated fat mass as the difference
between body weight and FFM and FFM index was calculated as FFM (kg)/height
(m)2. Total body muscle mass was calculated as previously described [12].
Muscle strength
Muscle function was assessed by handgrip strength measurement on the
same day of the recruitment before starting the HD session. A dynamometer
handle (JAMAR, Sammons Preston Rolyan, Bolingbrook, IL, USA) was used with
the purpose of measuring the maximum isometric strength of the hand and
forearm muscles. The test was conducted by performing three attempts with
each hand, and the mean of the strongest hand was used to determine muscle
strength [13]. The strength measurement was adjusted by sex and BMI.
Physical activity level
Two simple questions were administered to patients enrolled in the present
study. The first question concerned the self-reported frequency of physical ac-
tivity, including running, recreational walking, and so on, during leisure time. Six
answer options were available according to physical activity level: daily or almost
daily, four to five times a week, 2 to 3 times a week, once a week, less than once a
week, and almost never or never, as previously described by Tentori et al. [14].
Patients were divided into two groups: those who never exercised or reported
physical exercise less than once a week (inactive), and those who experienced
exercise more often (active) [14]. The second question regarded barriers to
physical activity in general or to lower physical activity levels than desired. It
consisted of investigating 23 barriers, as shown in Table 1 [15], designed on the
basis of previously validated questions [16].
Additionally, we asked patients to answer the Activities of Daily Living (ADL)
score questionnaire, consisting of six questions [17]. The maximum obtainable
scorewas 6. Participants reporting dependency in one or more daily activitywere
considered to have an ADL limitation [17].
BAIBA assay
Blood samples were obtained from HD patients immediately before the
second HD session of the week. We also collected blood samples from 43 healthy,
active individuals (control group). Blood (5 mL) was sampled in anticoagulant-
free tubes and kept at room temperature for 1 h before the serum was isolated.
Aliquots of serum were stored at 80C until analysis. BAIBA levels (mM) were
blind measured at the Neuroscience, Mental Health and Sense Organs Depart-
ment, Sapienza University of Rome, Rome, Italy. Standards of D,L-3-amino-
isobutyric acid and internal standard norvaline were used (Sigma Aldrich, Saint
Louis, MO, USA). High-performance liquid chromatography–grade acetonitrile
(Carlo Erba, Milan, Italy) and formic acid (Merck, Darmstadt, Germany) were also
used. Water was deionized and filtered with a Milli-Q Plus apparatus (Millipore
Corporation, Bedford, MA, USA).
Forty mL of serum samples were added to 160 mL of internal standard in
acetonitrile. The samples were vortex-mixed for 10 s and centrifuged at 14 000g
for 5 min and 100 mL of clean upper laver were diluted with 100 mL of 0.1% formic
acid and transferred in autosampler vials. Thirty mL were injected into the
chromatographic system. The high-performance liquid chromatography analysis
was performed using an Agilent Liquid Chromatography System series 1100
(Agilent Technologies, Santa Clara, CA, USA) including a binary pump, an auto-
sampler, a solvent degasser, and a column oven. The column was a Phenomenex
Luna HILIC (100 2.0mm, 3 mm; Phenomenex, Torrance, CA, USA) equippedwith
a security-guard precolumn (Phenomenex) containing the same packing mate-
rial. The column was maintained at room temperature. The mobile phase con-
sisted of a solution of 0.1% aqueous formic acid, 10 mM ammonium formate
Table 1
Patient-reported barriers to physical activity
Reported barriers Total participants (N ¼ 49) P value
Inactive
participants
(n ¼ 25)
Active
participants
(n ¼ 24)
1 Fatigue on the dialysis days 24 13 <0.001
2 Reduced walking ability 15 4 <0.001
3 Muscle pain 4 0 0.05
4 Pain during walking 7 3 0.17
5 Too many medical problems 10 1 0.002
6 Leg pain 7 1 0.002
7 Fear of getting hurt 6 0 0.01
8 Hip pain 8 2 0.04
9 “I don’t want to” 13 5 0.02
10 Fatigue on the nondialysis
days
10 2 0.008
11 Shortness of breath 14 7 0.04
12 Feet pain 4 1 0.19
13 Mood disturbances 1 0 0.49
14 Sadness 2 1 0.61
15 Anxiety 2 0 0.23
16 No exercise partner 1 0 0.49
17 No place to exercise 0 0 >0.99
18 Heart disease 4 2 0.42
19 Feeling too old 11 3 0.01
20 Ulcers on legs and feet 2 1 0.61
21 No one suggestedme to exercise 2 1 0.61
22 “I have no time” 1 3 0.61
23 Chest pain 1 0 0.49
Bold values indicate statistically significant P values.
Table 2
Patient characteristics (N ¼ 49)
Characteristics Mean  SD*
Sex (male:female) 36:13
Age, y 66.6  15.5
Dialysis vintage, mo 37 (13–92)
Body weight, kg 69.4  16.5
BMI, kg/m2 24.8  5.5
nPCR, g/kg/d 0.9  0.2
Creatinine, mg/dL 9.4  2.5
Urea, mg/dL 129.4  27
Kt/V 1.3  0.3
Albumin, g/dL 36.7  2.8
Lymphocytes, n/mm3 1.6  0.6
CRP, mg/dL 0.40 (0.11–0.81)
Cholesterol, mg/dL 146.5  34.9
Hb, g/dL 11.4  1.4
Comorbidities, yes/no
Hypertension 35/14
Diabetes mellitus 13/36
Hyperlipidemia 16/33
BMI, body mass index; CRP, C-reactive protein; Hb, hemoglobin; nPCR,
normalized protein catabolic rate; SD, standard deviation
* Median (interquartile range) is shown for nonnormally distributed variable
(dialysis vintage; C-reactive protein).
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at flow rate of 300 mL/min, using an elution gradient. The injection volume was
30 mL, and the total analysis run timewas 15min. Themass spectrometrymethod
was performed on a 3200 triple quadrupole system (Applied Biosystems, Foster
City, CA, USA) equipped with a turbo ion spray source. The detector was set in
positive ion mode. The ion spray voltage was set at 5000 V and the source
temperature was 400C, the collision activation dissociation gas was set at me-
dium value, and nitrogen was used as collision gas. The Q1 and Q3 quadrupoles
were tuned for the unit mass resolution. The instrument was set in the multiple
reaction monitoring mode. The specific ion (m/z) monitored was BAIBA (m/z
104.1/ m/z 87.0) with a dwell time of 300 ms. Mass spectrometer parameters
were optimized to maximize sensitivity. Data were acquired and processed by
Analyst 1.5.1 Software.
Statistical analyses
Patient characteristics were described using mean  SD for continuous
normally distributed variables and percent for dichotomous variables. Variables
that were not normally distributed were described using median with 25th and
75th percentiles. The proportion of patients self-reporting each barrier and the
average number of barriers perceived per patient were calculated. Chi-square,
Mann–Whitney, and Kruskall–Wallis tests were used to study the association
between reported barriers to physical activity and patient characteristics, the
association between barriers and reported levels of physical activity, and be-
tween BAIBA and levels of physical activity. Spearman’s correlation index was
used to assess associations between continuous measurements. Univariate lo-
gistic regression was used to evaluate odds ratios of factors associated with bi-
nary outcomes (e.g., active/inactive).
Multivariable regression and logistic regression analysis was used for the
same aims, adjusting for other patient characteristics often associated with
inactivity (e.g., age, sex, comorbidity). The best multivariable model was selected
byminimizing the Akaike information criterion. Physical activity was treated as a
categorical variable for these analyses. A standard two-tailed a (P < 0.05) was
considered statistically significant. All statistical analysis was performed in R v.
3.0.2.
Results
Patient’s characteristics
Fifty-two patients on HD were enrolled in the study. Three
participants were excluded: One was transferred to anotherdialysis center shortly after the beginning of the study, and two
were excluded because they did not perform bioimpedance
analysis. Therefore, 49 patients were studied (36 men and 13
women) with a mean age of 66.6  15.5 y. Median dialysis
vintage was 37 mo (interquartile range [IQR], 13–92) with a
mean Kt/V of 1.3  0.3. Fifteen patients were treated with high-
permeability membranes and 34 patients with low-permeability
membranes.
Characteristics of the enrolled patients are reported in Table 2.
The dialytic diagnosis was chronic renal failure due to unknown
or uncertain etiology in 15 patients, diabetic nephropathy in 8
patients, vascular diseases in 7 patients, chronic hereditary or
unknown origin glomerulonephritis in 7 patients, and other
diagnosis in 12 patients. The mean normalized protein catabolic
rate was 0.97  0.22 g/kg daily.
Of the enrolled patients, 22% presented two or more comor-
bidities, 71% suffered from arterial hypertension, 30% had
hyperlipidemia, and 26% had diabetes. The majority of the par-
ticipants were treated with antihypertensive therapies, eryth-
ropoietin, statins, potassium and phosphate binders, and vitamin
supplements. All patients were supplemented with folic acid.
There were 43 control participants (21 men, 22 women) with
a mean age of 66.7  1.1 y and a normal BMI (18.5–24.9 kg/m2).Self-reported physical activity
The enrolled patients were generally sedentary, as 51% re-
ported engaging in physical activity during leisure time less than
once per week, almost never, or never. We identified this group
as inactive. Only 26% of patients, identified as active, reported
doing physical activity during leisure time daily or almost daily
(four to five times a week). Forty-three patients acknowledged
having barriers to physical activity. Among them, 61% reported
having at least three barriers to physical activity. Only 6% of the
enrolled patients did not report any barriers to physical activity.
The most self-reported barrier was “fatigue on the dialysis days”
(73%), followed by “shortness of breath” (40%), “reduced walking
ability” (38%), “I don’t want to” (38%), and “heart disease” (36%).
“Feeling too old” as a barrier to physical activity was reported by
28% of patients. Only 8% patients reported muscle pain as a
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pants in the control group were active according to this
questionnaire.Fig. 2. BAIBA plasma levels in active and inactive hemodialysis patients, and in
controls. Box plot of BAIBA levels (mM) stratified by control group or “active” or
“inactive” patients on HD. Both “active” and “inactive” groups showed significantly
lower BAIBA levels versus control (P ¼ 0.0005 and P < 0.001, respectively). Lines
represent the median, 25th, and 75th percentiles, and the whiskers (error bars)
below and above the box indicate the 10th and 90th percentiles. BAIBA, beta-
aminoisobutyric acid; HD, hemodialysis.BAIBA, physical activity, and clinical parameters
BAIBA (mM) median value in all HD patients was 0.40 (IQR,
0.21–0.61), whereas in controls it was 0.98 (IQR, 0.63–1.66;
Fig. 1).
In univariate analysis, BAIBA levels were significantly lower in
HD patients than in healthy controls (P < 0.001; Fig. 1). Strati-
fying HD patients as active and inactive, both groups showed
significantly lower BAIBA levels than control (P ¼ 0.0005 and
P < 0.001, respectively; Fig. 2). BAIBA levels were lower in
inactive HD patients than in active HD patients, although not
statistically significant (P ¼ 0.09; Fig. 2).
No correlation was found among BAIBA levels, BMI, and body
composition parameters or with serum biomarkers, including
inflammatory status, with the exception of high-density lipo-
protein cholesterol (r¼ 0.40; P¼ 0.004), independently from the
level of physical activity. The type of dialysis (high or low
permeability membranes) did not influence BAIBA levels.
Among active and inactive patients, BAIBA levels did not
correlate with the number of comorbidities, but, after excluding
patients with a short dialysis vintage (3 mo), this correlation
was present (r ¼ 0.31; P ¼ 0.04). When considering the type of
comorbidities, patients without diabetes displayed higher me-
dian BAIBA levels than those with the disease (0.43 mM, IQR
0.26–0.85 versus 0.32 mM, IQR 0.14–0.43; P < 0.001) in both
groups of patients. No correlation was found between BAIBA
levels and hypercholesterolemia and/or statin treatment.
BAIBA levels correlated with the two most frequent barriers
reported by inactive patients (Table 1). In particular, “fatigue on
the dialysis days” correlated with BAIBA-circulating levels
(P ¼ 0.05). Also, inactive patients endorsing both “fatigue on the
dialysis days” and “reduced walking ability” showed lower me-
dian BAIBA levels (mM) versus HD patients not reporting these
two barriers, independently from the activity level (0.26 mM, 95%Fig. 1. BAIBA plasma levels in hemodialysis patients and in controls. Box plot of
BAIBA levels (mM) stratified by patients on HD or control group. BAIBA levels were
significantly lower in HD patients respect to control group (P < 0.001). Lines
represent the median, 25th, and 75th percentiles, and the whiskers (error bars)
below and above the box indicate the 10th and 90th percentiles. BAIBA, beta-
aminoisobutyric acid; HD, hemodialysis.confidence interval [CI] 0.12–0.43 versus 0.47 mM, 95% CI 0.29–
0.85, respectively; P ¼ 0.006; Fig. 3). No correlation between
BAIBA and handgrip strength measures has been documented.
Association between barriers and self-reported physical activity
In univariate analysis, “fatigue on the dialysis days” and
“reduced walking ability” were associated with inactivityFig. 3. BAIBA plasma levels and barriers to physical activity. Box plot of BAIBA levels
(mM) stratified by HD patients endorsing barriers “fatigue on the dialysis days” and
“reduced walking ability” (the two most frequent barriers in inactive patients) or
HD patients not self-reporting these two barriers. HD patients with the two barriers
had lower BAIBA levels (mM) than those patients without the two barriers, inde-
pendently from the activity level (0.26 mM, 95% CI, 0.12–0.43 versus 0.47 mM, 95% CI,
0.29–0.85, respectively; P ¼ 0.006). Lines represent the median, 25th, and 75th
percentiles, and the whiskers (error bars) below and above the box indicate the
10th and 90th percentiles. BAIBA, beta-aminoisobutyric acid; HD, hemodialysis.
*“Fatigue on the dialysis days” and “reduced walking ability.”
A. Molfino et al. / Nutrition 34 (2017) 101–107 105(P¼ 0.0003 and P¼ 0.0007, respectively), similarly to “fatigue on
the non-dialysis days” (P ¼ 0.008; Table 1). Patients who
endorsed “ulcers on legs and feet” or “feet pain” as a barrier were
not less likely to be active (P ¼ 0.68 and P ¼ 0.19, respectively).
Hip and leg pain were barriers associated with inactivity
(P ¼ 0.04 and P ¼ 0.002, respectively). Reporting “too many
medical problems” or “fear of getting hurt” was associated with
inactivity (P ¼ 0.002 and P¼ 0.01, respectively). “Feeling too old”
or “I don’t want to perform physical activity” were barriers
associated with inactivity (P ¼ 0.01 and P ¼ 0.02, respectively).
None of the participants endorsed any “lack of a location to ex-
ercise” as a barrier to physical activity. A significant correlation
between the number of barriers reported by each participant and
the number of comorbidities was detected (r ¼ 0.29; P ¼ 0.04).
No differences in blood pressure control and in other comor-
bidities, including diabetes or the presence of anemia, low Kt/v,
and low albumindwhich are generally associated with asthe-
niadwere found between active and inactive patients. In
multivariate analysis, after adjustment for age and sex, only the
number of barriers reported by each patient resulted in signifi-
cant associations with physical inactivity (odds ratio [OR], 4.22;
95% CI, 1.72–14.00; P ¼ 0.006).
Body composition, electrolytes, handgrip, and self-reported
physical activity
Body composition parameters between active and inactive
patients are reported in Table 3. In particular, active patients
showed higher intracellular water (%) (P ¼ 0.008), cellular mass
(%) (P ¼ 0.005), and body mass cell index (P ¼ 0.04). Serum
electrolytes, including sodium, did not differ between the two
groups (Table 3).
Handgrip strength (kg) was 24.5  9.7. No differences in
handgrip values between active and inactive patients were
observed (P ¼ 0.07; Table 3), however, there was a robust cor-
relation between total body muscle mass and handgrip strength
when considering all HD patients (r ¼ 0.55; P < 0.0001). BothTable 3
Body composition parameters, electrolytes, and functional assessment of all
patients (N ¼ 49)
Parameters Active
patients
(n ¼ 24)
Inactive
patients
(n ¼ 25)
P value
Body weight, kg 69.9  18.4 69.2  14.7 0.88
Body composition parameter
FFM, % 66.8  8.9 68.4  8.0 0.52
FFM, kg 46.5  13 47.2  11.2 0.83
FFM index, kg/m2 17.0  4.1 17.0  3.1 >0.99
Fat mass, % 33.2  8.9 31.6  8.0 0.52
Fat mass, kg 23.3  9.2 21.0  7.2 0.58
Intracellular water, liter 18.2  5.7 16.1  4.9 0.17
Intracellular water, % 51.2  7.3 44.5  9.5 0.008
Extracellular water, liter 17.5  5.6 20.3  5.9 0.1
Extracellular water, % 48.8  7.3 55.3  9.6 0.01
Body mass cell index, kg/m2 6.7  1.9 5.6  1.8 0.04
Cellular mass, kg 19.5  6.2 17  5.7 0.14
Cellular mass, % 42.3  7.3 35.9  7.8 0.005
Total body muscle mass, kg 22.6  4.9 21.5  4.8 0.43
Electrolytes
Sodium, mmol/L 137.30  3.81 136.36  4.52 0.44
Potassium, mmol/L 4.99  0.66 4.72  0.65 0.16
Phosphorus, mg/dL 4.69  1.33 4.74  1.10 0.89
Functional assessment
Handgrip, kg 27.1  10.0 22.0  8.8 0.07
ADL total score 6  0 5.8  1.1 0.07
ADL, activity of daily living; FFM, fat free mass
Bold values indicate statistically significant P values.active and inactive patients showed significant correlation be-
tween total body muscle mass and handgrip values (active pa-
tients: r ¼ 0.42; P ¼ 0.04; inactive patients: r ¼ 0.56; P ¼ 0.005).
Discussion
Several studies indicated that sedentary behavior in patients
on HD is associated with poor outcomes such as reduced survival
and higher mortality [3,18]. The National Kidney Foundation
recommends physical activity for patients on dialysis at least on
most days of the week [19]. Barriers to physical activity play an
important role in reducing the physical performance of this pa-
tient population. Similar to other studies [16,19,20], in the pre-
sent cross-sectional setting, the participation in physical activity
was limited, as 51% of enrolled HD patients reported partici-
pating in light activity during leisure time never, almost never, or
less than once per week, and 94% of patients reported facing
barriers to physical activity.
Among our patient cohort, participation in physical activity
was limited. Also, many reported barriers were significantly
associated with physical inactivity, including reduced walking
ability, too many medical problems, fear of getting hurt, not
wanting to exercise, and feeling too old. This list of barriers
suggests that physical inactivity is mainly due to a lack of
motivation. In this regard, as previously indicated [16], promot-
ing physical activity through tailored exercise interventions and
psychological interventions might help to reduce barriers to
physical activity in HD patients.
We found that active patients had higher intracellular water,
cellular mass (%), body mass cell index compared with inactive
patients, indicating that active patients have an increasedmuscle
compartment. It is likely that increased muscle mass was
determined by a higher level of physical activity and that the self-
reported level of physical activity, distinguished effectively active
from inactive patients.
The use of body composition analysis appears clinically useful
when identifying muscle mass derangement over time in inac-
tive patients, although some limitations related to bioimpedance
in HD patients should be considered [21]. However, this
approach is not achievable in the majority of HD units because of
the cost of the instrument and the lack of time to devote to this
analysis and its interpretation by health care professionals.
Therefore, the possible identification of a clinically useful
biomarker of muscle efficiency would represent a simple and
reproducible instrument to identify inactive patients.
Our data show that the myokine BAIBA, a small molecule
secreted from myocytes [6], is reduced in HD patients compared
with healthy and active controls, although no significant differ-
ences were observed between active and inactive patients, likely
due to the reduced sample size. Interestingly, no differences
between active and inactive patients were detected in terms of
anemia, low Kt/v, or low albumin, which are markers often
associated with the presence of asthenia.
A recent clinical trial demonstrated that plasma BAIBA con-
centrations increase with exercise and are inversely correlated
with metabolic parameters, such as fasting glucose, insulin, ho-
meostasis model assessment as an index of insulin resistance,
triglycerides, and total cholesterol [6]. Thus, BAIBA may play a
key role in exercise-induced protection from several metabolic
diseases and it is identified as an exercise-triggered signal with
relevant implications in the physiological mechanisms of phys-
ical exercise [22]. A previous study showed that BAIBA plasma
concentrations are inversely correlated with cardiometabolic
risk factors in humans and are increased during exercise training
A. Molfino et al. / Nutrition 34 (2017) 101–107106[6]. Moreover, it has been documented that BAIBA attenuates
insulin resistance and improves glucose tolerance [17,23].
Moreover, we found a positive correlation between BAIBA
plasma concentrations and high-density lipoprotein cholesterol,
whereas we did not observe any association between statin
treatment and BAIBA levels. Considering that statins often affect
muscle cell metabolism [24], the possibility that they may alter
BAIBA levels cannot be completely excluded. In adjusted ana-
lyses, we observed a correlation between BAIBA levels and the
number and types of comorbidities. In particular, patients on HD
with diabetes showed lower BAIBA levels than patients without
diabetes, pointing out a crucial role of metabolic derangement,
such as diabetes, in conditioning muscle performance.
Physical activity is considered an effective intervention for
the treatment of insulin resistance and type 2 diabetes [25].
During exercise, secretion of BAIBA from skeletal muscle is
increased, and BAIBA may contribute to exercise-induced pro-
tection from metabolic disease [6]. In experimental models, it
has been revealed that BAIBA attenuates insulin resistance and
inflammation induced by high-fat diet and prompts fatty acid
oxidation in skeletal muscle, highlighting how the beneficial
effects of exercise may be mediated through BAIBA [23].
Based on this evidence linking physical inactivity and BAIBA
levels in HD patients, we found that BAIBA levels significantly
correlated only with the two most frequent barriers endorsed by
inactive patients. In fact, patients reporting both “fatigue on the
dialysis days” and “reducedwalking ability” showed lower BAIBA
levels compared with those not reporting these two barriers.
Therefore, we believe that these two conditions may be markers
of quite important reduced physical activity, representing the
two most common barriers in the present sample and in other
larger cohorts [15,16]. On the other hand, no correlation between
BAIBA and handgrip measurements has, to our knowledge, been
documented. Also, no differences in handgrip values between
active and inactive patients has been observed. Although hand-
grip measurements were found to be predictive of muscle mass
in dialysis populations, this technique presents several limita-
tions related to the choice of arm, patients’ position, evaluation
period, and diagnostic criterion [26].
A number of limitations of the present study remain. Our
cohort of HD patients may not be representative of the entire
dialysis population. The small sample size of the present cohort
might have limited the possibility of recognizing associations
between patient characteristics, especially inflammatory profile,
and barriers to physical activity and/or BAIBA plasma levels.
Additionally, the instrument used to assess physical activity
during leisure time was not exhaustive and focused only on a
subset of activities, not taking into consideration other activities
that HD patients might perform. Increasing the number of
enrolled patients and identifying other activities performed
during leisure time might be a way to better understand how to
improve participation in physical activity and to possibly use
BAIBA as a targeted activity/inactivity biomarker in HD patients.
The control group included only physically active, healthy in-
dividuals, and we did not assess the role of BAIBA in a more
sedentary healthy group. We did not measure single nucleotide
polymorphisms of alanine-glyoxylate aminotransferase 2, which
might affect BAIBA plasma levels, as recently shown in healthy
volunteers [27]. We did not verify the kinetic of BAIBA before and
after exercise, and we did not measure BAIBA levels after dialysis
session. Moreover, a previous experience found a different trend
in BAIBA levels between uremic patients and healthy individuals,
although the methods used were different and with limited
specificity [28].Conclusions
Based on the findings of the present study, although BAIBA
levels were not different when comparing active and inactive
patients on HD, a relation in our cohort exists between the two
most common perceived barriers to physical activity and
BAIBA. A better understanding of the mechanism by which
BAIBA influences metabolic and functional responses to exer-
cise is therefore warranted in both experimental and clinical
settings.References
[1] Johansen KL, Delgado C, Bao Y, Tamura MK. Frailty and dialysis initiation.
Semin Dial 2013;26:690–6.
[2] Muscaritoli M, Molfino A, Bollea MR, Rossi Fanelli F. Malnutrition and
wasting in renal disease. Curr Opin Clin Nutr Metab Care 2009;12:378–83.
[3] Johansen KL, Kaysen GA, Dalrymple LS, Grimes BA, Glidden DV, Anand S,
et al. Association of physical activity with survival among ambulatory pa-
tients on dialysis: the comprehensive dialysis study. Clin J Am Soc Nephrol
2013;8:248–53.
[4] Fiaccadori E, Sabatino A, Schito F, Angella F, Malagoli M, Tucci M, et al.
Barriers to physical activity in chronic hemodialysis patients: a single-
center pilot study in an Italian dialysis facility. Kidney Blood Press Res
2014;39:169–75.
[5] Johansen KL, Sakkas GK, Doyle J, Shubert T, Dudley RA. Exercise counseling
practices among nephrologists caring for patients on dialysis. Am J Kidney
Dis 2003;41:171–8.
[6] Roberts LD, Boström P, O’Sullivan JF, Schinzel RT, Lewis GD, Dejam A, et al.
Beta-aminoisobutyric acid induces browning of white fat and hepatic beta-
oxidation and is inversely correlated with cardiometabolic risk factors. Cell
Metab 2014;19:96–108.
[7] Shimomura Y, Honda T, Shiraki M, Murakami T, Sato J, Kobayashi H, et al.
Branched-chain amino acid catabolism in exercise and liver disease. J Nutr
2006;136(Suppl 1):250–3.
[8] Harper AE, Miller RH, Block KP. Branched-chain amino acid metabolism.
Annu Rev Nutr 1984;4:409–54.
[9] Jankowska M, Debska-Slizien A, Rutkowski B. Bioelectrical impedance
analysis before versus after a hemodialysis session in evaluation of nutri-
tional status. J Ren Nutr 2006;16:137–40.
[10] Muscaritoli M, Molfino A, Chiappini MG, Laviano A, Ammann T, Spinsanti P,
et al. Anorexia in hemodialysis patients: the possible role of des-acyl
ghrelin. Am J Nephrol 2007;27:360–5.
[11] Molfino A, Don BR, Kaysen GA. Comparison of bioimpedance and dual-
energy x-ray absorptiometry for measurement of fat mass in hemodialy-
sis patients. Nephron Clin Pract 2012;122:127–33.
[12] Kaysen GA, Zhu F, Sarkar S, Heymsfield SB, Wong J, Kaitwatcharachai C,
et al. Estimation of total-body and limb muscle mass in hemodialysis pa-
tients by using multifrequency bioimpedance spectroscopy. Am J Clin Nutr
2005;82:988–95.
[13] Johansen KL, Dalrymple LS, Delgado C, Kaysen GA, Kornak J, Grimes B, et al.
Association between body composition and frailty among prevalent he-
modialysis patients: a US renal data system special study. J Am Soc Nephrol
2014;25:381–9.
[14] Tentori F, Elder SJ, Thumma J, Pisoni RL, Bommer J, Fissell RB, et al. Physical
exercise among participants in the Dialysis Outcomes and Practice Patterns
Study (DOPPS): correlates and associated outcomes. Nephrol Dial Trans-
plant 2010;25:3050–62.
[15] Bossola M, Pellu V, Di Stasio E, Tazza L, Giungi S, Nebiolo PE. Self-reported
physical activity in patients on chronic hemodialysis: correlates and bar-
riers. Blood Purif 2014;38:24–9.
[16] Delgado C, Johansen KL. Barriers to exercise participation among dialysis
patients. Nephrol Dial Transplant 2012;27:1152–7.
[17] Renal Data System. USRDS 2011 Annual Data Report. Bethesda, MD: Na-
tional Institutes of Health, National Institute of Diabetes and Digestive and
Kidney Diseases; 2011.
[18] Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-
Breen C, et al. Cardiovascular mortality risk in chronic kidney disease:
comparison of traditional and novel risk factors. JAMA 2005;293:1737–45.
[19] K/DOQI clinical practice guidelines for cardiovascular disease in dialysis
patients. Am J Kidney Dis 2005;45(suppl 3):S1–153.
[20] Johansen KL, Chertow GM, Ng AV, Mulligan K, Carey S, Schoenfeld PY, et al.
Physical activity levels in patients on hemodialysis and healthy sedentary
controls. Kidney Int 2000;57:2564–70.
[21] Essig M, Vrtovsnik F. How to evaluate body composition in chronic kidney
disease? Nephrol Ther 2008;4:92–8.
[22] Kammoun HL, Febbraio MA. Come on BAIBA light my fire. Cell Metab
2014;19:1–2.
A. Molfino et al. / Nutrition 34 (2017) 101–107 107[23] Jung TW, Hwang HJ, Hong HC, Yoo HJ, Baik SH, Choi KM. BAIBA attenuates
insulin resistance and inflammation induced by palmitate or a high fat diet
via an AMPK-PPARd-dependent pathway in mice. Diabetologia
2015;58:2096–105.
[24] Vrablik M, Zlatohlavek L, Stulc T, Adamkova V, Prusikova M, Schwarzova L,
et al. Statin-associated myopathy: from genetic predisposition to clinical
management. Physiol Res 2014;63:S327–34.
[25] Bogardus C, Ravussin E, Robbins DC, Wolfe RR, Horton ES, Sims EA. Effects
of physical training and diet therapy on carbohydrate metabolism in pa-
tients with glucose intolerance and noninsulin-dependent diabetes melli-
tus. Diabetes 1984;33:311–8.[26] Leal VO, Mafra D, Fouque D, Anjos LA. Use of handgrip strength in the
assessment of the muscle function of chronic kidney disease patients
on dialysis: a systematic review. Nephrol Dial Transplant 2011;26:
1354–60.
[27] Kittel A, Müller F, König J, Mieth M, Sticht H, Zolk O, et al. Alanine-glyox-
ylate aminotransferase 2 (AGXT2) polymorphisms have considerable
impact on methylarginine and b-aminoisobutyrate metabolism in healthy
volunteers. PLoS One 2014;9:e88544.
[28] Gejyo F, Kinoshita Y, Ikenaka T. Elevation of serum levels of beta-
aminoisobutyric acid in uremic patients and the toxicity of the amino
acid. Clin Nephrol 1977;8:520–5.
